Table 3. Subgroup analysis of the effect of randomised maternal treatment on antibody concentrations among infants at one year of age in groups according to maternal infection status.
| Albendazole | Praziquantel | |||||
|---|---|---|---|---|---|---|
| Antibody concentration | Effect of treatment in women with hookworm (aGMR, 95% CI)* | Effect of treatment in women without hookworm (aGMR, 95% CI)* | P-value for interaction | Effect of treatment in women with schistosomiasis (aGMR, 95% CI)* | Effect of treatment in women without schistosomiasis (aGMR, 95% CI)* | P-value for interaction |
| HiB (g/ml) | 1.03 (0.77–1.38) | 1.22 (0.93–1.61) | 0.39 | 0.98 (0.58–1.63) | 0.91 (0.73–1.14) | 0.80 |
| Diphtheria (Dtox IU/ml) | 0.89 (0.74–1.08) | 1.24 (1.04–1.47) | 0.01 | 0.88 (0.66–1.18) | 0.94 (0.82–1.08) | 0.70 |
| Hepatitis B (mIU/ml) | 0.93 (0.72–1.22) | 1.11 (0.88–1.40) | 0.33 | 1.17 (0.76–1.80) | 0.79 (0.66–0.95) | 0.09 |
| Pertussis toxin (Ptx EU/ml) | 1.10 (0.86–1.42) | 1.27 (1.00–1.61) | 0.39 | 1.03 (0.71–1.51) | 1.00 (0.82–1.23) | 0.89 |
| FHA (EU/ml) | 1.17 (0.98–1.41) | 1.02 (0.87–1.20) | 0.29 | 1.11 (0.87–1.42) | 0.99 (0.86–1.12) | 0.44 |
| Pertactin (Pm EU/ml) | 0.99 (0.83–1.18) | 1.07 (0.91–1.26) | 0.47 | 1.03 (0.78–1.38) | 0.95 (0.83–1.10) | 0.58 |
* Bias-corrected accelerated CIs computed by bootstrapping. All models are adjusted for randomised treatments, maternal age, gravidity, maternal education, household SES, maternal income, infant sex and previous infant malaria.